SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 19, 2013 (June 14, 2013)
REGENERON PHARMACEUTICALS, INC.
(Exact Name of Registrant as Specified in Charter)
(State or other jurisdiction
777 Old Saw Mill River Road, Tarrytown, New York 10591-6707
(Address of principal executive offices, including zip code)
(Registrants telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|¨||Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)|
|¨||Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)|
|¨||Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))|
|¨||Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))|
|Item 5.07||Submission of Matters to a Vote of Security Holders.|
At the 2013 Annual Meeting of Shareholders of Regeneron Pharmaceuticals, Inc. (the Company) held on June 14, 2013 (the Annual Meeting), the Companys shareholders voted on the matters set forth below.
Proposal 1 Election of Directors
The following nominees for Class I directors were elected to serve until the 2016 Annual Meeting of Shareholders and until a successor is duly elected based upon the following votes:
|Votes For||Votes Withheld||Broker Non-Votes|
Michael S. Brown, M.D.
Leonard S. Schleifer, M.D., Ph.D.
Eric M. Shooter, Ph.D.
George D. Yancopoulos, M.D., Ph.D.
Proposal 2 Ratification of Selection of Independent Registered Public Accountants
The proposal to ratify the appointment of PricewaterhouseCoopers LLP as the Companys independent registered public accounting firm for the fiscal year ending December 31, 2013 was approved based upon the following votes:
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|Date: June 19, 2013||REGENERON PHARMACEUTICALS, INC.|
|Name:||Joseph J. LaRosa|
Senior Vice President, General Counsel,